[PubMed] AMAG Pharmaceuticals and Palatin Technologies Enter Into Exclusive Licensing Agreement for North American Rights to RekyndaTM (bremelanotide), a Potential Treatment for a Common Female Sexual Disorder AMAG Pharmaceuticals.
Worth a shot
[DOI] [PMC free article] [PubMed] [Google Scholar] 94.Hsieh M.J., Liu H.T., Wang C.N., Huang H.Y., Lin Y., Ko Y.S., Wang J.S., Chang V.H., Pang J.S
Nie s dopuszczone do sprzeday jako produkty lecznicze ani suplementy diety, nie s przeznaczone do spoycia
Over the years, research and development have improved the reliability and affordability of this technology, making it more accessible
Portal and technical problems come up occasionally